EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Why Immunotherapy Fails in Multiple Myeloma

Luis Gerardo Rodríguez-Lobato, Aina Oliver-Caldés, David F. Moreno, Carlos Fernández de Larrea, Joan Bladé

Hemato · 2020

DOI: 10.3390/hemato2010001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hemato, 2020. Verfasst von Luis Gerardo Rodríguez-Lobato und 4 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 352 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma remains an incurable disease despite great advances in its therapeutic landscape. Increasing evidence supports the belief that immune dysfunction plays an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts have focused on harnessing the immune system to exert anti-myeloma effects with encouraging outcomes. First-in-class anti-CD38 monoclonal antibody, daratumumab, now forms part of standard treatment regimens in relapsed and refractory settings and is shifting to front-line treatments. However, a non-negligible number of patients will progress and be triple refractory from the first line of treatment. Antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptors (CAR) are being developed in a heavily pretreated setting with outstanding results. Belantamab mafodotin-blmf has already received approval and other anti-B-cell maturation antigen (BCMA) therapies (CARs and bispecific antibodies are expected to be integrated in therapeutic options against myeloma soon. Nonetheless, immunotherapy faces different challenges in terms of efficacy and safety, and manufacturing and economic drawbacks associated with such a line of therapy pose additional obstacles to broadening its use. In this review, we described the most important clinical data on immunotherapeutic agents, delineated the limitations that lie in immunotherapy, and provided potential insights to overcome such issues.

Zitieren

APA

Rodríguez-Lobato, L. G., Oliver-Caldés, A., Moreno, D. F., Larrea, C. F. D., & Bladé, J. (2020). Why Immunotherapy Fails in Multiple Myeloma. Hemato. https://doi.org/10.3390/hemato2010001

Vancouver

Rodríguez-Lobato LG, Oliver-Caldés A, Moreno DF, Larrea CFD, Bladé J. Why Immunotherapy Fails in Multiple Myeloma. Hemato. 2020. doi:10.3390/hemato2010001

BibTeX
@article{RodrguezLobato2020,
  author = {Rodríguez-Lobato, Luis Gerardo and Oliver-Caldés, Aina and Moreno, David F. and Larrea, Carlos Fernández de and Bladé, Joan},
  title = {Why Immunotherapy Fails in Multiple Myeloma},
  journal = {Hemato},
  year = {2020},
  doi = {10.3390/hemato2010001}
}
Kostenlos starten →